The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Curosurf (Poractant Alfa) Market Projected To Become By 2030 Based On Its 2026 Valuation?
The expansion witnessed in the historical timeframe resulted from a high occurrence of preterm births, the confirmed effectiveness in treating respiratory distress syndrome, the widespread implementation of neonatal intensive care units, clinical directives advocating surfactant therapy, and a decrease in neonatal mortality rates.
The projected growth during the forecast period is due to a worldwide increase in premature birth rates, the expansion of NICU infrastructure, improved access to neonatal care, a rising understanding of early RDS intervention, and continuous clinical validation.
Significant trends expected in the forecast period involve increased application within neonatal intensive care, wider adoption of synthetic surfactants, a stronger focus on preterm birth management, the standardization of RDS treatment protocols, and the expansion of hospital-based neonatal therapies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp
What Primary Drivers Are Shaping The Development Of The Curosurf (Poractant Alfa) Market?
The expanding occurrence of respiratory illnesses is anticipated to fuel the progression of the curosurf (poractant alfa) market in the future. These common conditions, which include asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, impact the lungs and respiration, resulting in breathing difficulties and diminished lung capacity. The increase in these disorders is attributable to rising air pollution, which worsens conditions like asthma, and an aging population, which contributes to a greater frequency of age-related ailments such as COPD. Poractant alfa is employed to manage neonatal respiratory distress syndrome by enhancing lung performance and facilitating breathing for premature infants, delivered through an endotracheal tube. For example, the National Library of Medicine, a US-based medical library, reported in December 2023 that the worldwide number of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and above is expected to climb by 23% by 2050, reaching almost 600 million. Consequently, the rising incidence of respiratory disorders is stimulating the expansion of the curosurf (poractant alfa) market.
What Segment Groups Are Identified Within The Curosurf (Poractant Alfa) Market?
The curosurf (poractant alfa) market covered in this report is segmented –
1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa
2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace
3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders
4) By End User: Hospitals, Clinics, Ambulance Services
What Trends Are Advancing Progress In The Curosurf (Poractant Alfa) Market?
Leading entities within the curosurf (poractant alfa) market are concentrating on creating advanced solutions, particularly new inhaled gene therapy, to tackle unaddressed requirements for respiratory conditions. This novel inhaled gene therapy represents a state-of-the-art method where therapeutic genetic material is administered straight to the lungs by means of inhalation, usually through aerosolized particles or extremely small particles. As an illustration, during November 2024, AlveoGene, a gene therapy developer situated in the UK, was granted Rare Pediatric Disease Designation (RPDD) by the FDA for its product AVG-002. This product is a pioneering inhaled gene therapy designed to target fatal neonatal surfactant protein B (SP-B) deficiency, which is a critical genetic condition resulting in respiratory failure among infants. SP-B deficiency, originating from mutations within the SFTPB gene, currently possesses restricted treatment alternatives, predominantly involving lung transplantation. AVG-002 leverages AlveoGene’s InGenuity platform to deliver a fully functional SP-B gene directly into the lungs, having demonstrated encouraging outcomes in preclinical investigations.
Which Companies Hold Significant Positions In The Curosurf (Poractant Alfa) Market?
Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A
Read the full curosurf (poractant alfa) market report here:
https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-
How Does The Curosurf (Poractant Alfa) Market Perform Across Major Global Regions?
North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Curosurf (Poractant Alfa) Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=19893&type=smp
Browse Through More Reports Similar to the Global Curosurf (Poractant Alfa) Market 2026, By The Business Research Company
Alfalfa Market Report 2026
https://www.thebusinessresearchcompany.com/report/alfalfa-global-market-report
Compound Camphor Ointment Market Report 2026
https://www.thebusinessresearchcompany.com/report/compound-camphor-ointment-global-market-report
Pharmaceutical Pellets Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-pellets-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model